603590 Stock Overview
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Beijing Konruns Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.48 |
| 52 Week High | CN¥41.95 |
| 52 Week Low | CN¥23.19 |
| Beta | 0 |
| 1 Month Change | -3.44% |
| 3 Month Change | -6.56% |
| 1 Year Change | -18.20% |
| 3 Year Change | -19.89% |
| 5 Year Change | -19.23% |
| Change since IPO | -15.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603590 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.0% | 4.9% | 2.1% |
| 1Y | -18.2% | -13.4% | -14.2% |
Return vs Industry: 603590 underperformed the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 603590 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
| 603590 volatility | |
|---|---|
| 603590 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603590 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603590's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 449 | Jianhua Liu | www.konruns.cn |
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations.
Beijing Konruns Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603590 fundamental statistics | |
|---|---|
| Market cap | CN¥4.61b |
| Earnings (TTM) | CN¥150.45m |
| Revenue (TTM) | CN¥920.01m |
30.7x
P/E Ratio5.0x
P/S RatioIs 603590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603590 income statement (TTM) | |
|---|---|
| Revenue | CN¥920.01m |
| Cost of Revenue | CN¥101.05m |
| Gross Profit | CN¥818.96m |
| Other Expenses | CN¥668.51m |
| Earnings | CN¥150.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 89.02% |
| Net Profit Margin | 16.35% |
| Debt/Equity Ratio | 4.5% |
How did 603590 perform over the long term?
See historical performance and comparison